Trial Profile
A Phase 3, Randomized, Open-Label, Multicenter Trial of Sym004 Versus Trifluridine/Tipiracil (TAS-102) in Patients With Chemotherapy-Refractory or Relapsed Metastatic Colorectal Carcinoma and Acquired Resistance to Anti-EGFR Monoclonal Antibody Therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Futuximab/modotuximab (Primary) ; Tipiracil/trifluridine
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Symphogen
- 31 Jan 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Oct 2018 New trial record